Frankfurt - Delayed Quote ? EUR enVVeno Medical Corporation (5HJ.F) Follow Compare 3.1000 +0.0200 (+0.65%) As of 8:10 AM GMT+1. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH Symposium Company to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00 PM Eastern Time - Click Here ... ACCESSWIRE ? 1 hour ago NVNBW NVNO NVNOW enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year Continued progress toward submission of 5th and final module of FDA premarket approval (PMA) application for VenoValve? in Q4 GLP study for enVVe? transcatheter-based replacement venous valve underway; On track to file IDE approval for pivotal trial ... ACCESSWIRE ? 19 days ago NVNBW NVNO NVNOW enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R) First wave of implants successfully completed with updated delivery system performing very well Company on schedule to be in position to apply for approval for enVVe pivotal trial mid-2025 IRVINE, CA / ACCESSWIRE / October 28, 2024 / enVVeno Medical ... ACCESSWIRE ? 22 days ago NVNBW NVNO NVNOW enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the pricing of an underwritten public ... ACCESSWIRE ? last month NVNBW NVNO NVNOW enVVeno Medical Corporation Announces Proposed Public Offering IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that it is proposing to offer and sell, ... ACCESSWIRE ? last month NVNBW NVNO NVNOW enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing MedTech Marketing Leader with Significant New Product Launch Experience for Cardiovascular Devices Key Addition to Commercial Team as Company Begins Planning for the VenoValve Monetization Several Upcoming Company Milestones Planned for Q4 of 2024 ... ACCESSWIRE ? 2 months ago NVNBW NVNO NVNOW enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R) VenoValve PMA Approval Application Process Consists of the Submission of 5 Modules to the FDA 4 Modules Have Now Been Submitted, Reviewed, and Approved by the FDA Company on Track to File the 5th and Final Module in Q4 2024 IRVINE, CA / ACCESSWIRE ... ACCESSWIRE ? 3 months ago NVNBW NVNO NVNOW Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation We can readily understand why investors are attracted to unprofitable companies. For example, although... Simply Wall St. ? 3 months ago NVNBW NVNO NVNOW enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Ended the quarter with $39.1 million cash and investments on hand sufficient to fund operations, through the end of 2025, including potential PMA approval of VenoValve? - Positive interim venous ulcer healing data showing significant improvement ... ACCESSWIRE ? 3 months ago NVNBW NVNO NVNOW enVVeno Medical to Participate in the Virtual Investor Closing Bell Series Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, June 27th at 4:00 PM ET IRVINE, CA / ACCESSWIRE / June 25, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting ... ACCESSWIRE ? 4 months ago NVNBW NVNO NVNOW Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting 91% of Venous Ulcer Patients Evaluated at One Year Have Either Fully Healed Ulcers or Ulcers That Have Improved 100% of Venous Ulcers with a Duration of One Year or Less Prior to VenoValve Surgery Have Fully Healed 89% of Venous Ulcers with a Duration ... ACCESSWIRE ? 4 months ago NVNBW NVNO NVNOW New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024 IRVINE, CA / ACCESSWIRE / June 17, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that new interim venous ulcer healing data ... ACCESSWIRE ? 4 months ago NVNBW NVNO NVNOW enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update - Ended the quarter with $42.9 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025- Positive 11-month topline efficacy data presented at the 46th Annual Charing ... ACCESSWIRE ? 6 months ago NVNBW NVNO NVNOW Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including: 9.29 Points for Patients at the Two-Year Milestone 8.08 Points for ... ACCESSWIRE ? 6 months ago NVNBW NVNO NVNOW New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that additional topline efficacy data from ... ACCESSWIRE ? 7 months ago NVNBW NVNO NVNOW enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve? PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024 IRVINE, CA / ACCESSWIRE ... ACCESSWIRE ? 7 months ago NVNBW NVNO NVNOW enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, March 21st at 12:00 PM ET IRVINE, CA / ACCESSWIRE / March 15, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting ... ACCESSWIRE ? 8 months ago NVNBW NVNO NVNOW Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting 97% of VenoValve Study Patients Showing Clinical Improvement at Six Months (as Measured by the Revised Venous Clinical Severity Score (rVCSS)) 74% of the Study Patients Showing Clinical Meaningful Benefit from the VenoValve at Six Months (Improvement ... ACCESSWIRE ? 8 months ago NVNBW NVNO NVNOW Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and... Simply Wall St. ? 8 months ago NVNBW NVNO NVNOW enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update $46.4 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025 Topline efficacy data for VenoValve? U.S. pivotal trial to be presented at the VENOUS2024 American ... ACCESSWIRE ? 8 months ago NVNBW NVNO NVNOW Performance Overview Trailing total returns as of 11/19/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return 5HJ.F S&P 500 YTD -34.32% +23.56% 1-Year -25.12% +30.56% 3-Year -51.56% +25.28%
